MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours-Reference-Cited by-同舟云学术

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours

Published:2016-03-08 Issue:8 Volume:114 Page:917-928
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Green Andrew R,Aleskandarany Mohammed A,Agarwal Devika,Elsheikh Somaia,Nolan Christopher C,Diez-Rodriguez Maria,Macmillan R Douglas,Ball Graham R,Caldas Carlos,Madhusudan Srinivasan,Ellis Ian O,Rakha Emad A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201646.pdf

Reference78 articles.

1. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340–350.

2. Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C, Albarakati N, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S (2014) DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol Oncol 8: 520–532.

3. Adem C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann LC, Jenkins RB (2004) ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 41: 1–11.

4. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT (2009) Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15: 3654–3662.

5. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534–8540.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes;Endocrinology;2024-08-27

2. EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth;Oncogene;2024-08-07

3. NOP16 promotes hepatocellular carcinoma progression and triggers EMT through the Keap1-Nrf2 signaling pathway;Technology and Health Care;2024-07-12

4. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer;International Journal of Surgical Pathology;2024-06-05

5. Tripartite Motif-Containing 2, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Triple-Negative Breast Cancer Treated with Chemotherapy;Cancers;2024-05-21